ENTITY
Kyowa Kirin Co Ltd

Kyowa Kirin Co Ltd (4151 JP)

48
Analysis
Health CareJapan
Kyowa Hakko Kirin Co.,Ltd. develops, manufactures, and markets pharmaceuticals. The Company's products include a protein produced by genetic recombination technology, an anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO), and a glycoprotein, human erythropoietin.
more
bullishFancl Corp
06 Aug 2019 20:56

Fancl: Explanatory Meeting On Kirin's Stake Acquisition Light on Details but Stay Positive Anyway

At about 3:30pm JST news broke that Kirin Holdings (2503 JP) would acquire a 30.3% stake in Fancl Corp (4921 JP) from the company's founder and his...

Logo
Mio Kato
536 Views
Share
12 May 2019 18:41

🇯🇵 Japan • Spring Results & Revisions & Market Update - Slip-Slidin' Away

SLIP-SLIDIN' AWAY - Japanese equities have lost 3.9% in the last holiday-shortened week and 4.6% or ¥30t since the bear-market rally peak on 17th...

Logo
501 Views
Share
22 Dec 2018 13:51

Japan Pharma - Domestic Market and Long Listed Drug Exposure

The Japanese government recently announced its decision to initiate an ad-hoc price reduction of ~4.35%, to be levied in October 2019, this will...

30 Oct 2018 23:21

Kyowa Hakko Kirin 3Q FY18 (YE Dec'18) Results - First Glance

Key highlights Continued genericization / ongoing price cuts led decline in domestic pharma sales by ~10% to ~¥43b However, overseas sales grew 16%...

24 Aug 2018 15:59

One-Time Income Resulted in Strong 1H FY18 Performance – Crysvita Is Key Driver.

We reiterate our “Equal-weight” rating on the stock post 1H FY18 (YE Dec-18) earnings KHK reported a decline in 1H FY18 sales (-2.0% to ¥1b) mainly...

x